Physician profile
Rakeshkumar Patel
NPI 1013998004
$641.78
in general payments reported to CMS, 2019-2025
9 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.43 · 2021: $35.73 · 2022: $224 · 2023: $144 · 2024: $95.04 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $363.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $155.80 | 2024-2025 | Zerbaxa, Recarbrio |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2023 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $105.64 | 2022 | |
| Amgen INC. | $105.64 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $45.52 | 2021-2025 | Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $35.92 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $31.52 | 2022-2024 | Invega Sustenna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2023 | Ofev |
| Grifols USA, LLC | $17.89 | 2024 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakeshkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.